Angiex Partners with Abzena to Advance Novel Cancer Therapy
Angiex has partnered with Abzena, a leading global biopharmaceutical solutions provider, to supply clinical trial material for its groundbreaking SLC Class TM SF-directed antibody-drug conjugate (ADC). This collaboration is a crucial step in advancing Angiex’s first-in-class ADC into clinical development, targeting the SLC transporter for precision cancer therapies. By leveraging Abzena’s expertise in manufacturing biologics, Angiex is positioned to deliver innovative oncology treatments with high potential for efficacy against difficult-to-treat cancers.
The coverage of this partnership by Outsourced Pharma highlights the importance of collaborative efforts in biopharma, particularly when it comes to developing highly specialized therapies. Outsourced Pharma is a respected media outlet focusing on the intersection of biopharmaceutical outsourcing and manufacturing, providing valuable insight into the partnerships that drive innovation in the industry. Their coverage underscores the significance of the Angiex-Abzena partnership in the broader context of drug development and clinical success.